Relationship among circulating inflammatory proteins, platelet gene expression, and cardiovascular risk

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 11, 2013, Pages 2666-2673

  McManus, David D ^a,b   Beaulieu, Lea M ^b   Mick, Eric ^b   Tanriverdi, Kahraman ^a,b   Larson, Martin G ^a,d,e   Keaney, John F ^a,b   Benjamin, Emelia J ^c,e   Freedman, Jane E ^b  

^a FRAMINGHAM HEART STUDY   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Boston University   (United States)

^e BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

cardiovascular disease; inflammation; mRNA platelets

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; MESSENGER RNA;

AGED; ALOX5 GENE; ARTICLE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CRP GENE; FEMALE; GENE EXPRESSION; HIGH THROUGHPUT SEQUENCING; HUMAN; IFIT1 GENE; IL6 GENE; INFLAMMATION; MALE; MEGAKARYOCYTE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PTGER2 GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; S100A9 GENE; SELENBP1 GENE; THROMBOCYTE; THROMBOCYTE FUNCTION; TLR2 GENE; TLR4 GENE; TNFRSF1B GENE; UPREGULATION;

EID: 84887050565     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.301112     Document Type: Article

References (62)

1. Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, Rieder MJ, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet. 2008;40:189-197.
2. Hakonarson H, Grant SF, Bradfeld JP, Marchand L, Kim CE, Glessner JT, et al. A genome-wide association study identifes KIAA0350 as a type 1 diabetes gene. Nature. 2007;448:591-594.
3. Kittleson MM, Ye SQ, Irizarry RA, Minhas KM, Edness G, Conte J V, et al. Identifcation of a gene expression profle that differentiates between ischemic and nonischemic cardiomyopathy. Circulation. 2004;110:3444-3451.
4. Benjamin EJ, Dupuis J, Larson MG, Lunetta KL, Booth SL, Govindaraju DR, et al. Genome-wide association with select biomarker traits in the Framingham Heart Study. BMC Med Genet. 2007;8(Suppl 1):S11.
5. Göring HH, Curran JE, Johnson MP, Dyer TD, Charlesworth J, Cole SA, et al. Discovery of expression QTLs using large-scale transcriptional pro-fling in human lymphocytes. Nat Genet. 2007;39:1208-1216.
6. Patti ME. Gene expression in the pathophysiology of type 2 diabetes mel-litus. Curr Diab Rep. 2004;4:176-181.
7. Freedman JE, Larson MG, Tanriverdi K, O'Donnell CJ, Morin K, Hakanson AS, et al. Relation of platelet and leukocyte infammatory transcripts to body mass index in the Framingham heart study. Circulation. 2010;122:119-129.
8. Sinnaeve PR, Donahue MP, Grass P, Seo D, Vonderscher J, Chibout SD, et al. Gene expression patterns in peripheral blood correlate with the extent of coronary artery disease. PLoS ONE. 2009;4:e7037.
9. Wingrove JA, Daniels SE, Sehnert AJ, Tingley W, Elashoff MR, Rosenberg S, et al. Correlation of peripheral-blood gene expression with the extent of coronary artery stenosis. Circ Cardiovasc Genet. 2008;1:31-38.
10. Radich JP, Mao M, Stepaniants S, Biery M, Castle J, Ward T, et al. Individual-specifc variation of gene expression in peripheral blood leukocytes. Genomics. 2004;83:980-988.
11. Moore DF, Li H, Jeffries N, Wright V, Cooper RA Jr, Elkahloun A, et al. Using peripheral blood mononuclear cells to determine a gene expression profle of acute ischemic stroke: a pilot investigation. Circulation. 2005;111:212-221.
12. Ma J, Dempsey AA, Stamatiou D, Marshall KW, Liew CC. Identifying leukocyte gene expression patterns associated with plasma lipid levels in human subjects. Atherosclerosis. 2007;191:63-72.
13. Healy AM, Pickard MD, Pradhan AD, Wang Y, Chen Z, Croce K, et al. Platelet expression profling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation. 2006;113:2278-2284.
14. Feezor RJ, Baker HV, Mindrinos M, Hayden D, Tannahill CL, Brownstein BH, et al.; Infammation and Host Response to Injury, Large-Scale Collaborative Research Program. Whole blood and leukocyte RNA isolation for gene expression analyses. Physiol Genomics. 2004;19:247-254.
15. Ridker PM. C-reactive protein and risks of future myocardial infarction and thrombotic stroke. Eur Heart J. 1998;19:1-3
16. Wang TJ, Larson MG, Levy D, Benjamin EJ, Kupka MJ, Manning WJ, et al. C-reactive protein is associated with subclinical epicardial coronary calcifcation in men and women: the Framingham Heart Study. Circulation. 2002;106:1189-1191.
17. Albert MA, Glynn RJ, Ridker PM. Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation. 2003;108:161-165.
18. Dhingra R, Gona P, Nam BH, D'Agostino RB Sr, Wilson PW, Benjamin EJ, et al. C-reactive protein, infammatory conditions, and cardiovascular disease risk. Am J Med. 2007;120:1054-1062.
19. Wilson PW, Nam BH, Pencina M, D'Agostino RB Sr, Benjamin EJ, O'Donnell CJ. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med. 2005;165:2473-2478.
20. Wang TJ, Nam BH, Wilson PW, Wolf PA, Levy D, Polak JF, et al. Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2002;22:1662-1667.
21. Zakai NA, Katz R, Jenny NS, Psaty BM, Reiner AP, Schwartz SM, et al. Infammation and hemostasis biomarkers and cardiovascular risk in the elderly: the Cardiovascular Health Study. J Thromb Haemost. 2007;5:1128-1135.
22. Blake GJ, Ridker PM. Novel clinical markers of vascular wall infamma-tion. Circ Res. 2001;89:763-771.
23. Eder K, Baffy N, Falus A, Fulop AK. The major infammatory mediator interleukin-6 and obesity. Infamm Res. 2009;58:727-736.
24. Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN, et al.; IL6R Genetics Consortium Emerging Risk Factors Collaboration. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379:1205-1213.
25. Hingorani AD, Casas J P. The interleukin-6 receptor as a target for prevention of coronary heart disease: A mendelian randomisation analysis. Lancet. 2012;379:1214-1224
26. Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, Mar R, et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med. 2004;350:29-37.
27. Luo Y, Xu Z, Wan T, He Y, Jones D, Zhang H, et al. Endothelial-specifc transgenesis of TNFR2 promotes adaptive arteriogenesis and angiogen-esis. Arterioscler Thromb Vasc Biol. 2010;30:1307-1314.
28. Burdo TH, Lo J, Abbara S, Wei J, DeLelys ME, Preffer F, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcifed coronary plaque in HIV-infected patients. J Infect Dis. 2011;204:1227-1236.
29. Martin-Ventura JL, Madrigal-Matute J, Martinez-Pinna R, Ramos-Mozo P, Blanco-Colio LM, Moreno JA, et al. Erythrocytes, leukocytes and platelets as a source of oxidative stress in chronic vascular diseases: detoxifying mechanisms and potential therapeutic options. Thromb Haemost. 2012;108:435-442.
30. Thivierge M, Rola-Pleszczynski M. Involvement of both cyclooxygen-ase and lipoxygenase pathways in platelet-activating factor-induced interleukin-6 production by alveolar macrophages. Ann N Y Acad Sci. 1994;725:213-222.
31. Argenbright LW, Barton RW. Interactions of leukocyte integrins with intercellular adhesion molecule 1 in the production of infammatory vascular injury in vivo. The Shwartzman reaction revisited. J Clin Invest. 1992;89:259-272.
32. Limb GA, Webster L, Soomro H, Janikoun S, Shilling J. Platelet expression of tumour necrosis factor-alpha (TNF-alpha), TNF receptors and intercellular adhesion molecule-1 (ICAM-1) in patients with proliferative diabetic retinopathy. Clin Exp Immunol. 1999;118:213-218.
33. Beaulieu LM, Lin E, Morin KM, Tanriverdi K, Freedman JE. Regulatory effects of TLR2 on megakaryocytic cell function. Blood. 2011;117:5963-5974.
34. Risitano A, Beaulieu LM, Vitseva O, Freedman JE. Platelets and platelet-like particles mediate intercellular RNA transfer. Blood. 2012;119:6288-6295.
35. Andonegui G, Kerfoot SM, McNagny K, Ebbert KV, Patel KD, Kubes P. Platelets express functional Toll-like receptor-4. Blood. 2005;106:2417-2423.
36. Scott T, Owens MD. Thrombocytes respond to lipopolysaccharide through Toll-like receptor-4, and MAP kinase and NF-kappaB pathways leading to expression of interleukin-6 and cyclooxygenase-2 with production of prostaglandin E2. Mol Immunol. 2008;45:1001-1008.
37. Srinivasan S, Mir F, Huang JS, Khasawneh FT, Lam SC, Le Breton GC. The P2Y12 antagonists, 2-methylthioadenosine 5′-monophosphate tri-ethylammonium salt and cangrelor (ARC69931MX), can inhibit human platelet aggregation through a Gi-independent increase in cAMP levels. J Biol Chem. 2009;284:16108-16117.
38. Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The Framingham Offspring Study. Design and preliminary data. Prev Med. 1975;4:518-525.
39. Schnabel R, Larson MG, Dupuis J, Lunetta KL, Lipinska I, Meigs JB, et al. Relations of infammatory biomarkers and common genetic variants with arterial stiffness and wave refection. Hypertension. 2008;51:1651-1657.
40. Harsch IA, Bergmann T, Koebnick C, Wiedmann R, Ruderich F, Hahn EG, et al. Adiponectin, resistin and subclinical infammation-the metabolic burden in Launois Bensaude Syndrome, a rare form of obesity. J Physiol Pharmacol. 2007;58 Suppl 1:65-76.
41. Fischer CP, Berntsen A, Perstrup LB, Eskildsen P, Pedersen BK. Plasma levels of interleukin-6 and C-reactive protein are associated with physical inactivity independent of obesity. Scand J Med Sci Sports. 2007;17:580-587.
42. Chen K, Li F, Li J, Cai H, Strom S, Bisello A, et al. Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med. 2006;12:425-432.
43. Alkharfy KM, Al-Daghri NM, Yakout SM, Ahmed M. Calcitriol attenuates weight-related systemic infammation and ultrastructural changes in the liver in a rodent model. Basic Clin Pharmacol Toxicol. 2013;112:42-49.
44. Sadagurski M, Norquay L, Farhang J, D'Aquino K, Copps K, White MF. Human IL6 enhances leptin action in mice. Diabetologia. 2010;53:525-535.
45. Poledne R, Lorenzová A, Stávek P, Valenta Z, Hubácek J, Suchánek P, et al. Proinfammatory status, genetics and atherosclerosis. Physiol Res. 2009;58(Suppl 2):S111-S118.
46. Cleland SJ, Sattar N, Petrie JR, Forouhi NG, Elliott HL, Connell JM. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci. 2000;98:531-535.
47. Browning LM, Krebs JD, Magee EC, Frühbeck G, Jebb SA. Circulating markers of infammation and their link to indices of adiposity. Obes Facts. 2008;1:259-265.
48. Shashkin PN, Brown GT, Ghosh A, Marathe GK, McIntyre TM. Lipopolysaccharide is a direct agonist for platelet RNA splicing. J Immunol. 2008;181:3495-3502.
49. Mitrou P, Lambadiari V, Maratou E, Boutati E, Komesidou V, Papakonstantinou A, et al. Skeletal muscle insulin resistance in morbid obesity: the role of interleukin-6 and leptin. Exp Clin Endocrinol Diabetes. 2011;119:484-489.
50. Empana JP, Jouven X, Canouï-Poitrine F, Luc G, Taffet M, Haas B, et al. C-reactive protein, interleukin 6, fbrinogen and risk of sudden death in European middle-aged men: the PRIME study. Arterioscler Thromb Vasc Biol. 2010;30:2047-2052.
51. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327-334.
52. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, et al. Infammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351:2599-2610.
53. Hwang SJ, Park KW, Kwon DA, Kang HJ, Koo BK, Chae IH, et al.; Korea Stent Thrombosis Investigators. High plasma interleukin-6 is associated with drug-eluting stent thrombosis: possible role of infammatory cytokines in the development of stent thrombosis from the Korea Stent Thrombosis Registry. Circ J. 2011;75:1350-1357.
54. Rowley JW, Oler AJ, Tolley ND, Hunter BN, Low EN, Nix DA, et al. Genome-wide RNA-seq analysis of human and mouse platelet transcrip-tomes. Blood. 2011;118:e101-e111.
55. Lindemann S, Tolley ND, Dixon DA, McIntyre TM, Prescott SM, Zimmerman GA, et al. Activated platelets mediate infammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol. 2001;154: 485-490.
56. de Mello VD, Kolehmainen M, Pulkkinen L, Schwab U, Mager U, Laaksonen DE, et al. Downregulation of genes involved in NFkappaB activation in peripheral blood mononuclear cells after weight loss is associated with the improvement of insulin sensitivity in individuals with the metabolic syndrome: the GENOBIN study. Diabetologia. 2008;51:2060-2067.
57. Mraz M, Lacinova Z, Drapalova J, Haluzikova D, Horinek A, Matoulek M, et al. The effect of very-low-calorie diet on mRNA expression of infam-mation-related genes in subcutaneous adipose tissue and peripheral mono-cytes of obese patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2011;96:E606-E613.
58. Camargo A, Ruano J, Fernandez JM, Parnell LD, Jimenez A, Santos-Gonzalez M, et al. Gene expression changes in mononuclear cells in patients with metabolic syndrome after acute intake of phenol-rich virgin olive oil. BMC Genomics. 2010;11:253.
59. Xiong J, Miller VM, Hunter LW, Li Y, Jayachandran M. Leukocyte-and platelet-derived microvesicle interactions following in vitro and in vivo activation of toll-like receptor 4 by lipopolysaccharide. PLoS ONE. 2011;6:e25504.
60. Bendinelli P, Matteucci E, Dogliotti G, Corsi MM, Banf G, Maroni P, et al. Molecular basis of anti-infammatory action of platelet-rich plasma on human chondrocytes: mechanisms of NF-κB inhibition via HGF. J Cell Physiol. 2010;225:757-766.
61. Kim H, Kang HJ, You KT, Kim SH, Lee KY, Kim TI, et al. Suppression of human selenium-binding protein 1 is a late event in colorectal carci-nogenesis and is associated with poor survival. Proteomics. 2006;6: 3466-3476.
62. Liu DQ, Li LM, Guo YL, Bai R, Wang C, Bian Z, et al. Signal regulatory protein alpha negatively regulates beta2 integrin-mediated mono-cyte adhesion, transendothelial migration and phagocytosis. PLoS ONE. 2008;3:e3291.